AbbVie (ABBV) Company Report

AbbVie has executed roughly 30 transactions since early 2024, focusing on small bolt-on and platform deals (e.g., Nimble peptide platform, Capstan, 8Rx siRNA, Gubra obesity asset) while retaining capacity for larger M&A if compelling.
The company reaffirms high single-digit revenue growth from 2024–2029 with EPS expected to grow faster via operating margin expansion—driven by SG&A leverage—while maintaining R&D spend at ~15% of sales.
Skyrizi grew 46% YoY in Q3 2025 across IBD and psoriatic disease, benefiting from unique eight-week dosing and an on-body device; subcutaneous induction data in Crohn’s due H1 2026.
The Parkinson’s franchise led by Vyalev 24-hour infusion pump targets >$400 million in 2025 revenue, with full-year guidance >$1 billion and multi-billion peak potential alongside tavapadon.

4 days ago

Transcript

AbbVie outlines capital deployment and pipeline strategy at Piper Sandler Conference

ABBV

M&A

Guidance Update

AbbVie has completed ~30 smaller-scale BD transactions since early 2024, focusing on platform and single-asset deals across immunology, oncology, neuroscience, eye care and obesity, and remains open to larger near-term revenue deals if compelling.
The company maintains high single-digit revenue growth guidance for 2024–2029, with EPS expected to grow faster via operating margin expansion driven by SG&A leverage and continued R&D investment at ~15% of sales.
Skyrizi grew 46% YoY in Q3 with balanced IBD and psoriatic disease uptake; an on-body sub-Q induction device for Crohn’s is expected to initiate submission after H1 2026 data.
Pipeline highlights include phase II combination studies in IBD (TL1A, α4β7, IL-1), an obesity asset from the Gubra acquisition, and Rinvoq’s vitiligo label expansion targeting >$2 billion peak sales.
In neuroscience, Vyalev’s 24-hour sub-Q infusion is guiding >$400 million in 2025 sales with a >$1 billion peak outlook alongside filed tavapadon; brexalosin neuroplastogen shows a rapid 2-hour psychedelic effect in MDD with a favorable 5-HT2B antagonism safety profile.

4 days ago

Transcript

AbbVie outlines growth strategy and pipeline at Piper Sandler Healthcare Conference

ABBV

Guidance Update

New Projects/Investments

AbbVie is deploying capital through ~30 small platform and single-asset transactions since early 2024 to bolster its pipeline and sustain growth into the next decade.
The company reiterated high-single-digit revenue growth guidance for 2024–2029, with EPS expected to outpace sales via stable R&D spend (~15% of sales) and operating margin expansion through SG&A leverage.
Commercially, Skyrizi grew 46% YoY in Q3, the IL-23 category in ulcerative colitis rose from ~4% to ~40% in 18 months, and a sub-Q induction on-body device submission is planned for H1 2026.
Pipeline highlights include Rinvoq in vitiligo (>$2 billion peak sales), Vyalev Parkinson’s pump guiding >$400 million in 2025 and >$1 billion soon plus tavapadon filing, and Brotosilicin featuring a 2-hour neuroplastogen profile with 5-HT2B antagonism to reduce cardiac risk.

4 days ago

Transcript

AbbVie to feature new data at ASH 2025 Congress

ABBV

AbbVie will present new clinical data across multiple blood cancers—MM, FL, CLL, DLBCL, AML and AL—highlighting T-cell engagers, BCL-2 inhibitors and ADCs at the 2025 ASH Congress.
In the Phase 3 EPCORE FL-1 trial, epcoritamab + rituximab + lenalidomide reduced risk of progression/death by 79% (HR 0.21), with ORR 95.7% vs 81.0%, and CR 74.5% vs 43.3% for R2 alone.
The Phase 3 CLL17 trial met non-inferiority for fixed-duration venetoclax+obinutuzumab and venetoclax+ibrutinib versus continuous ibrutinib, with 3-year PFS ~81% (VO), 81.0% (I) and 79.4% (VI).
Early data show etentamig + pomalidomide/dexamethasone achieved ORR 81% and ≥VGPR 72% in R/R MM, and PVEK + venetoclax + azacitidine achieved CR 63.3% in newly diagnosed AML unfit for intensive chemotherapy.

5 days ago

Press Release

AbbVie receives positive reimbursement recommendation for SKYRIZI in ulcerative colitis

ABBV

Canada’s Drug Agency recommended SKYRIZI® (risankizumab) for reimbursement under public drug plans for adults with moderately to severely active ulcerative colitis who have failed prior therapies.
The recommendation is informed by evidence from pivotal phase 3 trials, including MOTIVATE, ADVANCE, FORTIFY (for Crohn’s disease) and INSPIRE, COMMAND (for ulcerative colitis).
AbbVie signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance to finalize reimbursement terms for SKYRIZI® in ulcerative colitis.

Nov 28, 2025, 12:01 PM

Press Release

AbbVie announces FDA approval of EPKINLY+R2 for relapsed/refractory follicular lymphoma

ABBV

Product Launch

The FDA approved EPKINLY® (epcoritamab-bysp) combined with rituximab and lenalidomide (R2) as the first bispecific antibody combination therapy for adult patients with relapsed/refractory follicular lymphoma after ≥1 prior systemic therapy.
In the Phase 3 EPCORE FL-1 trial, EPKINLY + R2 reduced the risk of disease progression or death by 79% (HR 0.21; 95% CI: 0.13–0.33; p<0.0001) and achieved an 89% overall response rate (vs 74% for R2 alone).
Among patients receiving EPKINLY + R2, 74% attained a complete response (vs 43% with R2), and median progression-free survival was not reached vs 11.2 months for R2.
This approval represents EPKINLY’s third indication and converts its accelerated approval granted in June 2024 into full approval; the safety profile was consistent with known regimen effects.

Nov 18, 2025, 5:47 PM

Press Release

Xilio Therapeutics presents Phase 2 vilastobart data in MSS mCRC

ABBV

Presented 40% objective response rate (ORR) in heavily pre-treated MSS mCRC patients without liver metastases and high plasma TMB, with statistically significant correlation (p = 0.05) between TMB status and response.
As of May 12, 2025, 44 patients were treated with vilastobart plus atezolizumab (100 mg Q6W and 1200 mg Q3W), including 27 without liver metastases and 24 evaluable for plasma TMB.
Approximately 55% of non-MSI-H CRC patients were plasma TMB-high (≥10 mutations/Mb), highlighting the potential of plasma-based TMB assays over traditional tissue-based tests.
Combination therapy was generally well-tolerated, with most treatment-related adverse events Grade 1–2, a 5% discontinuation rate and 7% incidence of colitis.

Nov 7, 2025, 2:05 PM

Press Release

Xilio presents masked immunotherapy data at SITC 40th Annual Meeting

ABBV

Xilio’s masked T cell engager programs leveraging ATACR and SEECR formats demonstrated potent preclinical anti-tumor activity with reduced systemic toxicity, supporting a best-in-class potential across multiple targets.
Efarindodekin alfa (XTX301) Phase 1 monotherapy in 62 advanced solid tumor patients showed generally well-tolerated safety up to the RP2D and two partial responses, including a confirmed PR with a 33% tumor reduction.
In Phase 2 for vilastobart plus atezolizumab in MSS mCRC, deep ctDNA reductions (≥75%) correlated with radiographic responses, and two patients achieved endoscopic complete responses with undetectable ctDNA.
Xilio nominated its PSMA ATACR candidate in Q3 2025 and plans to nominate CLDN18.2 (Q4 2025) and STEAP1 SEECR (H1 2026) candidates, with at least two IND filings anticipated in 2027.
Data were presented at SITC (Nov 5–9, 2025), including posters on masked engagers (Abstract 972), XTX301 PD data (Abstract 567), ctDNA biomarker analysis (Abstract 541) and pTMB enrichment (Abstract 1315).

Nov 7, 2025, 2:01 PM

Press Release

AbbVie to Showcase Epcoritamab Data at ASH 2025

ABBV

Genmab and AbbVie will present over 20 epcoritamab abstracts, including seven oral presentations, at the ASH Annual Meeting (Dec 6–9).
Data highlight epcoritamab’s potential in first- and second-line follicular lymphoma and first-line diffuse large B-cell lymphoma.
Phase 3 EPCORE FL-1 trial results (epcoritamab + rituximab + lenalidomide) in relapsed/refractory FL accepted for an oral presentation.
Genmab will host a 2025 R&D Update and ASH Data Review webcast on December 11.

Nov 3, 2025, 2:05 PM

Press Release

AbbVie reports Q3 2025 results and raises full-year outlook

ABBV

Earnings

Guidance Update

M&A

AbbVie delivered adjusted EPS of $1.86 and net revenues of $15.8 billion in Q3, up 8.4% operationally, beating guidance; raised 2025 EPS to $10.61–$10.65 and sales to $60.9 billion, with Q4 revenue and EPS guidance at $16.3 billion+ and $3.32–$3.36
Immunology revenues grew 11.2% to $7.9 billion, led by SKYRIZI ($4.7 billion, +46% op) and RINVOQ ($2.2 billion, +34.1% op), offsetting HUMIRA’s 55.7% decline to $993 million; neuroscience sales rose 19.6% to $2.8 billion, with VYALEV up 40% to $138 million
Invested $84 billion in R&D since 2013, plans $9 billion of 2025 R&D expense, and maintains ~90 pipeline programs; key upcoming catalysts include tavapadon, PVEK approvals, expanded indications for RINVOQ/EPKINLY/QULIPTA/UBRELVY, and late-stage data for lutikizumab and Temab-A
Generated $13 billion of free cash flow YTD Q3 (cash $5.6 billion), increased quarterly dividend by 5.5% to $1.73 (payable Feb 2026), and acquired Gilgamesh (bretisilocin) and Capstan to expand immunology and psychiatry pipelines

Oct 31, 2025, 1:00 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for AbbVie.

Q3 2025

Oct 31, 2025

→

Q2 2025

Jul 31, 2025

→

Q1 2025

Apr 25, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Robert A. Michael say about margins?What are AbbVie's strategic priorities?How is AbbVie positioned vs competitors?How did AbbVie do last quarter?

AbbVie (ABBV)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Robert A. Michael

Azita Saleki-Gerhardt

Jeffrey R. Stewart

Perry C. Siatis

Scott T. Reents

Board Members

Brett J. Hart

Edward J. Rapp

Frederick H. Waddell

Jennifer L. Davis

Melody B. Meyer

Rebecca B. Roberts

Robert J. Alpern

Roxanne S. Austin

Susan E. Quaggin

Thomas C. Freyman

Thomas J. Falk

William H.L. Burnside

Analyst Coverage

Christopher Schott

Mohit Bansal

Steve Scala

Terence Flynn

Vamil Divan

David Risinger

Asad Haider

Carter L. Gould

Courtney Breen

Geoffrey Meacham

Luisa Hector

Trung Huynh

Chris Shibutani

Geoff Meacham

James Shin

Matthew Phipps

Simon Baker

Timothy Anderson

Alexandria Hammond

Christopher Raymond

David Amsellem

David Aslam

Evan Seigerman

Gary Nachman

Jon Win

Tim Anderson

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent